



PHARMACY BULLETIN

EDITION 16 ISSUE 12


PPUKM

2015

RESULTS OF JKTU 4/2015

The last and final meeting for the Drug & Therapeutics Committee in 2015 was recently held on 18th December 2015. Results of the meeting will be implemented starting **1st February 2016** for both new drugs and add-on indication/prescriber. Below are the results:

New Drug Approved

Drug Name	Indication & Dosage	Approved PPUKM Policy
1. INDACATEROL MALEATE & GLYCOPYRONIUM BROMIDE FIXED DOSE COMBINATION 110/50 MCG INHALATION POWDER HARD CAPSULE. (ULTIBRO BREEZHALER®) 	Indication: Once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) (moderate to severe COPD) Dose: 110/50mcg capsule once daily using Breezhaler Inhaler.	Prescriber: A*: Respiratory Specialists only. Use existing budget. To share allocation with Tiotropium (Spiriva), Symbicort and Indacaterol (Onbreeze) up to RM400,000 .00 per year. Maximum usage of Indacaterol is combined as above.

Newly Added Allocation/Strength/Prescriber

i) TENOFOVIR DISOPROXIL FUMARATE 300MG + EMTRICITABINE 200MG TAB (TENVIR-EM®)	Additional allocation for 70 patients.	Prescriber : A* : Infectious Disease Specialist only.
ii) LAMIVUDINE 150MG + ZIDOVUDINE 300MG TAB (COMBIVIR-G)	Additional allocation for 30 patients.	
iii) EFAVIRENZ 600MG CAPSULE (STOCRIN-G)	Additional allocation for 100 patients.	

During the meeting, it was also announced that the Customs Department has amended the list of zero rated drugs. It is postulated that a saving of RM3 million will be obtained from this new amendment which will be effective from **1st January 2016**.

The dates for next year's meeting has also been set in the meeting. The dates are (subject to changes):

- ♦ JKTU 1/2016 : **4th March 2016** (Drug Utilization Review)
- ♦ JKTU 2/2016 : **3rd June 2016** (New Drug/ Additional Indication/Strength/Prescriber)
- ♦ JKTU 3/2016 : **23rd September 2016** (New Drug/ Additional Indication/Strength/Prescriber)
- ♦ JKTU 4/2016 : **16th Disember 2016** (New Drug/ Additional Indication/Strength/Prescriber)

Announcements from Pharmacy Department





RELOCATION OF DRUGS COLLECTION FOR 'POLIKLINIK WARGA' & ENDOSCOPY CENTRE

Effective **2nd January 2016**, all prescriptions and drug collections from Poliklinik Warga & Endoscopy Centre will be changed to **Outpatient Pharmacy (Main Pharmacy)** at Ground Floor. Currently patients obtain their drug supply from First Floor Satellite Pharmacy, but due to substantial increase in number of prescriptions, this action is deemed necessary to reduce patient's waiting time.

We hope that this information can be disseminated to **ALL STAFFS & PATIENTS**. A special counter dedicated for PPUKM/UKM staffs will be made available at **Counter 8** (Special Counter for disable/wheelchair patients, elderly & staffs). It is also hoped that after this implementation, First Floor Satellite Pharmacy will be able to achieve its Key Performance Indicator (92% of patients received their medications less than 20 minutes. Your understanding and cooperation in this matter is highly appreciated. Thank you.

NEW ITEMS IN KEDAI FARMASI

Kedai Farmasi of PPUKM has added a few **NEW** items. Below are the details:

No	Item/Drug & Price	Indication	Dose & Administration
1	Tab Abiraterone 250mg (Zytiga) RM11,434.20/120 tab	In combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed after a docetaxel - based chemotherapy regimen.	1000mg (4 tabs) as a single daily dose. Take at least 1 hr before or 2hrs after meals. Swallow whole do not chew.
2	Cap Sunitinib 12.5mg (Sutent) RM 2,292.25/28 tabs 	Treatment of GI stromal tumor (GIST) after disease progression or intolerance to imatinib mesylate, advanced renal cell carcinoma (RCC) & unresectable/metastatic, well differentiated pancreatic neuroendocrine tumours (pNET) with disease progression.	GIST & RCC: 50mg once daily for 4 weeks followed by a 2-week rest period. May increase or reduce dose in 12.5mg increments based on individual safety & tolerability. Max 87.5mg pNET: 37.5mg once daily without a schedule rest period. Max 50mg.
3	Inj Palonosetron 250mcg/5mL (Aloxi) RM252.60/inj	Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy & acute nausea & vomiting associated with highly emetogenic cancer chemotherapy in adults.	250ug administered as single IV bolus approximately 30 minutes before start of chemotherapy
4	Inj Bortezomib 3.5mg (Velcade) RM3,571.15/inj 	Treatment of multiple myeloma & treatment of mantle cell lymphoma in patients who have received at least 1 prior therapy.	1.3mg/m ² administered as a 3-5 sec IV bolus inj twice weekly for 2 weeks (days 1,4,8, & 11) followed by a 10 day rest period (days 12-21). Extended therapy of >8 cycles: as per standard schedule or once/wk (days 1,8,15 & 22)
5	Fosfomycin Trometamol (Monurol) 3g sachet RM38/sachet	<ul style="list-style-type: none"> Treatment of acute uncomplicated lower UTI. Prophylaxis in diagnosis & surgical transurethral procedures. 	<ul style="list-style-type: none"> Acute uncomplicated lower UTI : 1 sachet as a single dose. Recurrent cystitis : 1 sachet every 10 days for 3 months
6	Artelac Night Time Gel RM101.20/10g tube 	To calm & relieve persistent dry eye symptoms due to chronic tear deficiency. Contains: 2mg carbomer (to bind moisture to eye's surface for continued relief), medium chain triglycerides (triglycerides) to support the lipid layer of the tear film, sterilized water, sorbitol, cetrimide and sodium hydroxide.	Apply once at night before sleep. The 10g tube is intended to last for 28 days of supply.
7	Tab Perampanel 2mg, 4mg & 8mg (Fycompa) RM3.90/tab of 2mg RM7.90/ tab of 4mg RM 16.60/tab of 8mg	Used with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and primary generalized tonic-clonic seizures in people with epilepsy who are 12 years of age and older.	Initially 2mg daily, may be increased by 2-mg increments to a maintenance dose 4-8mg daily. Maximum is 12mg daily. 

A publication of
DRUG INFORMATION CENTRE, PHARMACY DEPARTMENT, HCTM, PPUKM.

Izyan Diyana Binti Ibrahim
izyandi@ppukm.ukm.edu.my
03-91455415

<http://www.p pukm.ukm.my/farmasi/>

Michelle Tan Hwee Pheng
hptan@ppukm.ukm.edu.my
03-91455401